How do cancer cells escape tightly controlled regulatory circuits that link their proliferation to extracellular nutrient cues? An emerging theme in cancer biology is the hijacking of normal stress response mechanisms to enable growth even when nutrients are limiting. Pancreatic ductal adenocarcinoma (PDA) is the quintessential aggressive malignancy that thrives in nutrient-poor, hypoxic environments. PDAs overcome these limitations through appropriation of unorthodox strategies for fuel source acquisition and utilization. In addition, the interplay between evolving PDA and whole-body metabolism contributes to disease pathogenesis. Deciphering how these pathways function and integrate with one another can reveal novel angles of therapeutic attack.

Significance: Alterations in tumor cell and systemic metabolism are central to the biology of pancreatic cancer. Further investigation of these processes will provide important insights into how these tumors develop and grow, and suggest new approaches for its detection, prevention, and treatment. Cancer Discov; 5(12); 1247–61. ©2015 AACR.

Key Concepts and Relevance
  • Cancers have heightened metabolic requirements for cell growth that need to be coordinated with nutrient supply.

  • PDAs must contend with further metabolic constraints due to their hypovascular, fibrotic microenvironment, and ensuing hypoxia and limited nutrient availability. To support tumor growth, PDAs acquire multiple alterations in metabolic circuitry and activation of nutrient scavenging processes—autophagy and macropinocytosis.

  • PDA development is also influenced by conditions that change whole-body metabolism (type II diabetes and obesity), and reciprocally PDA incites systemic metabolic alterations (cachexia and PDA-induced diabetes).

  • How these processes are activated, integrated, and regulated has started to come into focus.

  • The recent advances in understanding these metabolic alterations provide new insights into PDA pathogenesis and suggest paths forward for the development of improved therapeutics and diagnostics.

Characteristic Features of Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDA) is among the most lethal of all cancer types, with approximately 48,000 new cases and 40,000 deaths annually in the United States (1). It is projected to become the second leading cause of cancer-related death by 2020 in the United States and has a 5-year survival rate of only approximately 6%, which has changed little over the last four decades. Invasive PDA arises through multistage genetic and histologic progression from microscopic precursor lesions designated as pancreatic intraepithelial neoplasia (PanIN) that are believed to develop and progress asymptomatically over several decades (Fig. 1A; refs. 1–3).

Figure 1.

Schematic of the multistage progression of PDA. A, PDA arises from the multistage progression of precursor lesions known as PanIN. B, KRAS mutations are an early event in disease pathogenesis, present in the great majority of early-stage PanIN lesions. Mutations in a series of tumor suppressors occur as later events, and contribute to disease progression. C, PDA is also associated with evolving alterations in the tumor microenvironment, including increasing fibrosis and extracellular matrix deposition (desmoplasia) and recruitment of immune and inflammatory cells. Increasing desmoplasia accompanies progressive disease (as indicated) and creates intratumoral pressure that compresses the vasculature, resulting in limited blood flow to the tumor and consequent hypoxia and low nutrient delivery. In turn, PDA cells exhibit activation of nutrient scavenging pathways (autophagy and macropinocytosis) that support tumor cell growth. Although autophagy activation is a late event in PDA tumorigenesis, the precise temporal dynamics of macropinocytosis is as yet unknown (dotted box).

Figure 1.

Schematic of the multistage progression of PDA. A, PDA arises from the multistage progression of precursor lesions known as PanIN. B, KRAS mutations are an early event in disease pathogenesis, present in the great majority of early-stage PanIN lesions. Mutations in a series of tumor suppressors occur as later events, and contribute to disease progression. C, PDA is also associated with evolving alterations in the tumor microenvironment, including increasing fibrosis and extracellular matrix deposition (desmoplasia) and recruitment of immune and inflammatory cells. Increasing desmoplasia accompanies progressive disease (as indicated) and creates intratumoral pressure that compresses the vasculature, resulting in limited blood flow to the tumor and consequent hypoxia and low nutrient delivery. In turn, PDA cells exhibit activation of nutrient scavenging pathways (autophagy and macropinocytosis) that support tumor cell growth. Although autophagy activation is a late event in PDA tumorigenesis, the precise temporal dynamics of macropinocytosis is as yet unknown (dotted box).

Close modal

An early event during malignant transformation is the acquisition of activating mutations in the KRAS oncogene at codons 12, 13, and 61, which occurs in >90% of patients with PDA. PDAs are highly “addicted” to this oncogene for multiple parameters influencing tumor initiation, progression, and maintenance, as demonstrated using genetically engineered mouse (GEM) models and human PDA cell lines (4–9). In addition, inactivating mutations and deletions of the tumor-suppressor genes TP53, CDKN2A, and SMAD4 are also frequently observed and occur later during disease progression (Fig. 1B). Metastatic lesions exhibit extensive conservation of genomic alterations with matched primary PDA, although specific mutations in the primary tumor (in SMAD and TP53) are associated with increased propensity for metastatic dissemination (10–12). GEM models incorporating these genetic alterations have provided functional validation of their roles in progression of PanIN to PDA and in metastasis (4, 6, 13–16).

The identification of these recurrent mutations and additional less common genetic alterations in PDA has not yet pointed to key targets that are readily inactivated by existing drugs (17, 18). Although KRAS is clearly a critical driver of tumorigenesis, pharmacologic KRAS inhibitors remain elusive. Thus, the present standard of care involves conventional cytotoxic agents that can yield significant responses but in most patients have limited efficacy (1). These issues highlight the need to further probe the biology of PDA in order to uncover novel vulnerabilities of the cancer cells. Indeed, recent studies have revealed a profound rewiring of metabolic pathways activated downstream of oncogenic KRAS that is essential for PDA growth and holds promise as a source of targets for new therapeutic strategies (19, 20). Activation of these pathways may also be linked to the unique microenvironment of PDA, which is characterized by a dense fibrotic stromal component (desmoplasia; ref. 21). Although other cancer types, such as breast, prostate, and ovarian cancers, also display prominent stromal infiltration, PDA stands out by the remarkable extent of its desmoplastic reaction, which often forms the bulk of the tumor mass. This heterogeneous infiltrate—consisting of activated fibroblasts [pancreatic stellate cells (PSC)] and diverse inflammatory and immune cells—co-evolves with the tumor cells and influences PDA progression and response to therapy (22–28). An important consequence of the dense stroma is the generation of high levels of solid stress and fluid pressure in the tumors and compression of the vasculature, which creates a highly hypoxic and nutrient-poor microenvironment (Fig. 1C; refs. 22, 29–31). Despite these harsh environmental conditions, PDA cells are able to survive and thrive. How do these cells subsist in the presence of low levels of nutrients derived from the circulation? Which pathways are activated that allow unbridled proliferative capacity? This review focuses on the recently discovered unorthodox strategies used by PDA cells to acquire nutrients and use them for generation of energy and as building blocks for de novo synthesis of proteins, lipids, and nucleic acids. We also provide an overview of how PDA pathogenesis is influenced by conditions that alter whole-body metabolism, such as diabetes and obesity. Finally, we discuss the translational potential of exploiting knowledge about pancreatic cancer metabolism for improved diagnostics and therapy for this disease.

Uncoupling Nutrient Sensing in Cancer

The adaptive changes in tumor metabolism can broadly be categorized into alterations in the sensing, acquisition, and utilization of nutrients, and elimination of toxic by-products. In noncancerous cells, the utilization of nutrients is tightly linked to their abundance via the action of multiple nutrient-sensing pathways (32). These sensors are finely tuned to detect drops in cellular nutrient levels or conversely to respond to signs of plenitude, and include adenosine monophosphate–activated protein kinase (AMPK; ref. 33) and mTOR complex 1 (mTORC1; ref. 34), respectively. For example, AMPK triggers two tightly coordinated processes upon detection of reduced energy charge (ATP:AMP ratio): one is to shut down energy-intensive anabolic processes, such as protein and lipid biosynthesis. The second is to increase energy generation both by activating autophagy—a nutrient scavenging–recycling pathway that provides fuel sources by breaking down superfluous cellular components into their constituent building blocks—and by enhancing mitochondrial oxidative phosphorylation. Additional sensors for lipids, AAs, and other key metabolites act to restore homeostasis through similar principles (32). An emerging view is that cancer cells adapt to life under limiting nutrient conditions by breaking these basic rules and removing the dichotomy between states of biosynthesis and catabolism. This bypass endows cancer cells with sustained growth even in challenging environments where nutrients and oxygen are scarce, or following metastasis to distant organ sites. How this occurs has been the focus of extensive study over the last several years (35), and much evidence suggests that cancer cells hijack and modify normal cellular homeostatic response mechanisms to maintain an unrestricted rate of growth.

Although relatively little is known to date about how sensing mechanisms themselves may be subverted or appropriated in PDA, significant advances have been made with regard to how these tumors obtain nutrients and channel them into distinct biochemical pathways. PDA and other KRAS-driven cancers thrive in poorly perfused, hypovascular conditions by simultaneously upregulating both nutrient acquisition and utilization pathways (36, 37). This metabolic reprogramming may enable PDA cells to more efficiently maintain adequate intracellular nutrient levels despite limited external supply, providing them with a competitive growth advantage compared with law-abiding normal cells. Thus, severe nutrient and oxygen shortage may function as strong selective pressures favoring survival of aggressive tumor cells able to withstand such harsh environmental conditions. Conversely, the acquired dependence of PDA on these pathways creates new vulnerabilities that can be targeted therapeutically.

Anabolic Glucose Metabolism

To fuel their elevated demand for energy and macromolecular biosynthesis, many cancers show augmented nutrient acquisition that is coupled to increased flux through downstream metabolic pathways. Thus, it is not surprising that mutations in KRAS and other canonical oncogenes (e.g., AKT, MYC, and PI3K) and tumor suppressors (e.g., TP53, RB, and PTEN) that drive accelerated growth also directly reprogram cellular metabolism by acting at both of these levels (38–40). A common theme associated with these central cancer pathways is the promotion of glucose metabolism, which serves as a major nutrient source for the production of ATP and provides building blocks for anabolic processes. In keeping with their poor perfusion, the overall levels of glucose and its rate of uptake are thought to be modest in PDA compared with other cancer types (29). Measurement of steady-state metabolite levels suggests that glucose concentrations are not significantly elevated in most PDAs compared with adjacent pancreatic tissue (29). Nevertheless, among PDAs, higher levels of glucose uptake and expression of the primary glucose transporter GLUT1 (encoded by SLC2A1) correlate with worse prognosis (41, 42). Moreover, alterations in glucose delivery and utilization are required for PDA tumorigenesis, and mutant KRAS serves as a major regulator of these processes. Using a GEM model with expression of mutant KRAS under a doxycycline-inducible promoter, it was shown that KRAS silencing markedly reduces glucose uptake in PDA in vivo and in derivative cell lines, associated with downregulation of GLUT1 and of multiple glycolytic enzymes (Fig. 2; refs. 8, 37).

Figure 2.

Alterations in metabolite utilization in PDA. A, KRAS promotes glucose metabolism in PDA cells by upregulating the GLUT1 transporter and driving glycolysis through induction of the expression of multiple glycolytic enzymes. In addition, glycolytic intermediates are shunted toward biosynthetic pathways, including the nonoxidative arm of the PPP for synthesis of DNA and RNA, and the HBP, which generates precursors necessary for generation of glycoproteins, glycolipids, proteoglycans, and glycosaminoglycans. B, in addition, PDA cells have enhanced activity of the monocarboxylate transporters MCT1 and MCT4, which shuttle lactate in order to prevent intracellular accumulation and subsequent decreases in cytosolic pH. C, KRAS also activates and reprograms glutamine metabolism. A proportion of glutamate is used to fuel NADPH production via the aspartate–malate shunt, thus contributing to maintenance of reduced glutathione levels and redox balance. The enzymes whose expression levels are regulated by mutant KRAS are indicated in blue. HBP, hexosamine biosynthesis pathway; PPP, pentose phosphate pathway; TCA, tricarboxylic acid.

Figure 2.

Alterations in metabolite utilization in PDA. A, KRAS promotes glucose metabolism in PDA cells by upregulating the GLUT1 transporter and driving glycolysis through induction of the expression of multiple glycolytic enzymes. In addition, glycolytic intermediates are shunted toward biosynthetic pathways, including the nonoxidative arm of the PPP for synthesis of DNA and RNA, and the HBP, which generates precursors necessary for generation of glycoproteins, glycolipids, proteoglycans, and glycosaminoglycans. B, in addition, PDA cells have enhanced activity of the monocarboxylate transporters MCT1 and MCT4, which shuttle lactate in order to prevent intracellular accumulation and subsequent decreases in cytosolic pH. C, KRAS also activates and reprograms glutamine metabolism. A proportion of glutamate is used to fuel NADPH production via the aspartate–malate shunt, thus contributing to maintenance of reduced glutathione levels and redox balance. The enzymes whose expression levels are regulated by mutant KRAS are indicated in blue. HBP, hexosamine biosynthesis pathway; PPP, pentose phosphate pathway; TCA, tricarboxylic acid.

Close modal

In PDA cells grown in vitro, as in most cultured cells, glycolysis predominates over mitochondrial oxidative phosphorylation of pyruvate, regardless of oxygen tension—a phenomenon known as the Warburg effect. This is mediated by inhibition of pyruvate dehydrogenase by pyruvate dehydrogenase kinase (PDK) and by increased lactate dehydrogenase (LDH) activity. The decreased fractional utilization of pyruvate for ATP generation in the mitochondria allows for the channeling of glycolytic intermediates into important anabolic pathways, including the hexosamine biosynthesis pathway (HBP), which generates substrates for protein and lipid glycosylation, and to the nonoxidative arm of the pentose phosphate pathway (PPP), which generates ribose-5-phosphate for nucleotide biosynthesis. Unlike the well-known oxidative PPP, this latter pathway does not produce NADPH, thereby necessitating other mechanisms for redox control (see below). KRAS mediates these changes by transcriptional induction of genes encoding rate-limiting enzymes in both pathways (Fig. 2A; ref. 8). These alterations in glucose metabolism are required for the full tumorigenic growth of PDA cells, as demonstrated by the decreased ATP levels and reduced growth of PDA xenografts treated with a small-molecule inhibitor of LDHA (FX11, which acts by competing with NADH binding; ref. 43). Similarly, knockdown of key KRAS-regulated enzymes in the nonoxidative PPP or the hexosamine pathway slows the growth of murine PDA cell lines in vitro and suppresses tumorigenicity upon subcutaneous implantation (8, 44).

This dependence on glycolysis also presents additional demands on mobilization and excretion of potentially toxic by-products. Enhanced shuttling of lactate via the activity of monocarboxylate transporters MCT1 and MCT4 (encoded by the SLC16A1 and SLC16A3 genes, respectively) was shown to be essential to prevent intracellular accumulation of lactate and decreased cytosolic pH in PDA cells (Fig. 2B; refs. 45, 46). These transporters are overexpressed in PDA compared with normal tissue and are required for PDA growth (45), with MCT4 playing a predominant role, supporting the physiologic importance of this detoxification process. PDA cells also show elevated levels of the lactate receptor GPR81, which regulates expression of lactate transporters, and CD147, an essential MCT chaperone protein (47). Thus, in response to increased metabolic demand, PDA cells coordinately enhance glucose utilization and lactate mobilization (44).

The signaling pathways controlling glucose metabolism downstream of KRAS have not been completely resolved, although MEK clearly has an important role. Treatment of PDA cell lines with MEK inhibitors markedly impairs glycolysis and reduces expression of glycolytic enzymes, which at least partially involves modulation of MYC transcriptional activity (8). PDA shows multiple additional mechanisms for altering glucose metabolism beyond direct KRAS signaling. For example, it appears that hypoxia and the hypoxia-inducible factor 1α (HIF1α) contribute to upregulation of glycolysis and HBP genes in PDA (44). The FOXM1 and KLF4 transcription factors have also been proposed as positive and negative regulators, respectively, of LDHA levels and glycolytic activity (48, 49). In addition to their regulation at the transcriptional level, several glycolytic enzymes are controlled by posttranscriptional mechanisms (50, 51). In PDA, one such mechanism involves removal of inhibitory acetylation on lysine 5 of LDHA by SIRT2, a deacetylase that senses increases in NAD+:NADH ratio (52). The full spectrum of mechanisms regulating glucose metabolism are no doubt complex and likely involve multiple additional levels of KRAS-dependent and KRAS-independent control that remain to be deciphered. Moreover, as metabolic pathways may operate differently in vitro and in vivo, the precise utilization of glucose in PDA will require further study.

Glutamine Metabolism and Redox Homeostasis

In addition to glucose, highly proliferative cancer cells rely on glutamine—the most abundant and versatile AA in the cell cytoplasm—as a fuel source for ATP generation and for macromolecular biosynthesis. Glutamine is a nonessential AA that functions as a precursor and amine donor for the generation of other AAs as well as nucleotides and hexosamine, and as a donor of carbon skeletons for replenishment of tricarboxylic acid (TCA) cycle intermediates (anaplerosis). Although many tissues can synthesize glutamine, cancer cells show addiction to glutamine in culture (53, 54), and thus this AA becomes conditionally essential for growth. The first step in glutamine catabolism involves its conversion to glutamate catalyzed via the glutaminase enzymes (GLS1 and GLS2). Glutamate, in turn, is a source of α-ketoglutarate (α-KG)—a TCA cycle intermediate as well as a coenzyme for DNA and protein modifying dioxygenases—generated via the function of glutamate dehydrogenase (GLUD1) in the mitochondria or by transamination in the cytosol or mitochondria. This latter reaction also produces nonessential AAs. Glutamate is also a precursor of glutathione, the major antioxidant in the cell (55).

As noted above, KRAS-mutant PDA cells do not effectively generate NADPH from the PPP; rather these cells produce NADPH through a noncanonical glutamine–glutamate metabolism pathway (Fig. 2C). This pathway involves conversion of glutamate to α-KG and aspartate in the mitochondria catalyzed by aspartate transaminase 2 (GOT2; ref. 56). Aspartate is then trafficked to the cytosol, where it is converted sequentially to oxaloacetate, malate, and pyruvate, via a GOT1–malate dehydrogenase–malic enzyme (ME) cascade that generates NADPH. This pathway is under the control of KRAS, which promotes the transcriptional upregulation of GOT1 and repression of GLUD1, and is necessary for redox balance and growth of PDA cells in vitro and in vivo. In addition, enhanced catalytic activity of GOT2 via lysine acetylation has been reported to be required for redox homeostasis in PDA cells (57). KRAS also mitigates the high levels of ROS generated in rapidly proliferating cells by activating the NRF2 transcription factor that induces an antioxidant gene expression program (58).

The diverse roles of glutamine in fueling tumor cell metabolism have spurred the development of inhibitors targeting enzymes along the glutamine metabolism pathway, including GLS inhibitors that are currently being evaluated clinically (see Table 1). However, it should be noted that recent studies have suggested that glutamine may not be a major contributor to anaplerosis in some cancer types in vivo, and therefore the dependence of cultured cell lines on exogenous glutamine may not always be conserved in primary tumors (59, 60). Likewise, GLS (and thus glutamine–glutamate conversion) may be dispensable for the growth of some tumors. Nevertheless, this would not undermine the importance of the GOT2–GOT1–ME pathway, which can use glutamate regardless of its source. Thus, these downstream components may offer additional therapeutic targets irrespective of the potential utility of GLS inhibitors in PDA.

Table 1.

Clinical trials targeting metabolism in PDA

TargetAgentTrial designNCT number
Pyruvate dehydrogenase and α-KG dehydrogenase CPI-613 + gemcitabine Phase I/II NCT00907166 
Lysosome HCQ + gemcitabine/nab-paclitaxel Phase I/II NCT01506973 
 HCQ + gemcitabine Phase I/II NCT01128296 
 HCQ + proton beam (neoadjuvant) Phase II NCT01494155 
 HCQ + gemcitabine/nab-paclitaxel (neoadjuvant) Phase II NCT01978184 
VDR Paricalcitol + gemcitabine/abraxane (neoadjuvant) Randomized, pharmacodynamic study NCT02030860 
PPARγ Pioglitazone Phase II NCT01838317 
Mitochondrial complex I Metformin Phase I NCT01954732 
 Metformin + gemcitabine or nab-paclitaxel Phase I NCT02336087 
 Metformin + rapamycin Phase I/II NCT02048384 
 Metformin + gemcitabine Phase II NCT02005419 
 Metformin/gemcitabine Phase II NCT01210911 
HMG-CoA reductase Atorvastatin + metformin Observational NCT02201381 
Glutaminase CB-839 Phase I NCT02071862 
TargetAgentTrial designNCT number
Pyruvate dehydrogenase and α-KG dehydrogenase CPI-613 + gemcitabine Phase I/II NCT00907166 
Lysosome HCQ + gemcitabine/nab-paclitaxel Phase I/II NCT01506973 
 HCQ + gemcitabine Phase I/II NCT01128296 
 HCQ + proton beam (neoadjuvant) Phase II NCT01494155 
 HCQ + gemcitabine/nab-paclitaxel (neoadjuvant) Phase II NCT01978184 
VDR Paricalcitol + gemcitabine/abraxane (neoadjuvant) Randomized, pharmacodynamic study NCT02030860 
PPARγ Pioglitazone Phase II NCT01838317 
Mitochondrial complex I Metformin Phase I NCT01954732 
 Metformin + gemcitabine or nab-paclitaxel Phase I NCT02336087 
 Metformin + rapamycin Phase I/II NCT02048384 
 Metformin + gemcitabine Phase II NCT02005419 
 Metformin/gemcitabine Phase II NCT01210911 
HMG-CoA reductase Atorvastatin + metformin Observational NCT02201381 
Glutaminase CB-839 Phase I NCT02071862 

Abbreviations: HCQ, hydroxychloroquine; VDR, vitamin D receptor.

An Unusual Diet: A Protumorigenic Role for Autophagy in PDA

PDAs use an intriguing set of scavenging mechanisms that support growth and may mitigate the limited delivery of nutrients from the vasculature that characterizes these tumors (Fig. 3A). These include autophagy (also known as macroautophagy), which is a highly conserved cellular catabolic process that mediates degradation of macromolecules as well as whole organelles. Autophagy involves sequestration of cytoplasmic contents within a double membrane vesicle (the autophagosome), which eventually fuses with lysosomes, forming autolysosomes where cargo is degraded. Products of autolysosome digestion (AAs, fatty acids, nucleosides) are recycled back to the cytoplasm to fuel biosynthetic and bioenergetic reactions and ultimately protect the cell during conditions of cellular stress such as nutrient starvation (61). In addition, autophagy functions to remove misfolded proteins, damaged organelles, and protein aggregates and therefore provides the cell with an important quality control mechanism. Deregulation of these essential protective functions of basal autophagy has been implicated in the pathogenesis of degenerative and immune disorders as well as in aging (62, 63). Of the numerous stimuli that can activate autophagy above baseline levels, the best characterized and most potent is nutrient starvation, which activates AMPK and turns off mTORC1 (Fig. 3A). These kinases phosphorylate key proteins controlling autophagy initiation, namely ULK1/2 and ATG13, to induce (AMPK) or suppress (mTORC1) autophagosome formation. Autophagy can also be activated in response to glucose deprivation in an ULK1-independent manner by increased ammonia levels generated via compensatory AA catabolism (64). Thus, decreases in extracellular and intracellular nutrient levels promote autophagy, providing an adaptive response geared toward restoring cellular homeostasis. Extensive studies of the functions of autophagy in cancer reveal context- and stage-specific roles. Although its quality control activity serves as a barrier to tumorigenesis through suppression of genomic instability, oxidative stress, and chronic tissue damage, established cancers exploit the macromolecular recycling and detoxifying functions of autophagy to gain a growth advantage and protect the tumor cell (65–74).

Figure 3.

Nutrient scavenging in PDA converges at the lysosome for breakdown of intracellular and extracellular cargo. A, PDA cells show enhanced autophagy activation and macropinocytosis in vitro and in vivo. Autophagy involves formation of double membrane vesicles that surround a portion of cytoplasm thus encapsulating cargo material (protein, lipid, organelles) that is delivered to lytic organelles (lysosome) for breakdown. Positive (AMPK and VPS34) and negative (mTORC1) kinase regulators of autophagy are indicated. Macropinocytosis, the bulk uptake of extracellular material, occurs via plasma membrane invagination and generation of internalized macropinosomes. These cargo-laden vesicles similarly fuse with lysosomes for efficient degradation of the internalized material. Therefore, lysosomes are a key central delivery port for substrates destined for breakdown and serve to recycle the constituent building blocks and support cellular metabolism. Drugs that modulate different aspects of these pathways are shown. B, resident lysosomal enzymes and their substrates and final products are listed. BAFA1, Bafilomycin A1; EIPA, 5-(N-Ethyl-N-isopropyl)amiloride; HCQ, hydroxychloroquine.

Figure 3.

Nutrient scavenging in PDA converges at the lysosome for breakdown of intracellular and extracellular cargo. A, PDA cells show enhanced autophagy activation and macropinocytosis in vitro and in vivo. Autophagy involves formation of double membrane vesicles that surround a portion of cytoplasm thus encapsulating cargo material (protein, lipid, organelles) that is delivered to lytic organelles (lysosome) for breakdown. Positive (AMPK and VPS34) and negative (mTORC1) kinase regulators of autophagy are indicated. Macropinocytosis, the bulk uptake of extracellular material, occurs via plasma membrane invagination and generation of internalized macropinosomes. These cargo-laden vesicles similarly fuse with lysosomes for efficient degradation of the internalized material. Therefore, lysosomes are a key central delivery port for substrates destined for breakdown and serve to recycle the constituent building blocks and support cellular metabolism. Drugs that modulate different aspects of these pathways are shown. B, resident lysosomal enzymes and their substrates and final products are listed. BAFA1, Bafilomycin A1; EIPA, 5-(N-Ethyl-N-isopropyl)amiloride; HCQ, hydroxychloroquine.

Close modal

Autophagy Is Constitutively Active and Required for PDA Growth

Autophagy can be gauged by the cleavage and lipidation of the LC3 protein followed by its integration into the autophagosomal membrane (Table 2). By these measures, the great majority of PDA cell lines exhibit high basal autophagy compared with control immortalized pancreatic ductal cells (61). The use of additional assays confirms a true increase in autophagic activity (flux) rather than a block in the pathway. Moreover, autophagy is active in PDA cell lines even when grown in standard tissue culture conditions, suggesting this process is uncoupled from external nutrient availability. This is functionally important because treatment with the antimalarial drug chloroquine—which inhibits autophagy by increasing lysosomal pH—or knockdown of essential autophagy genes (ATG5 or ATG7) strongly inhibits PDA cell proliferation under full nutrient conditions (75). Correspondingly, treatment with the chloroquine analogue hydroxychloroquine (HCQ) suppresses tumorigenic growth in PDA patient–derived xenograft (PDX) and cell line–derived xenograft models, and in the KrasG12D;Trp53+/− GEM harboring established PDAs or advanced PanIN lesions. Likewise, knockdown of ATG5/ATG7 inhibits the growth of human PDA cell line xenografts.

Table 2.

Assays for monitoring autophagy

AssayVisualizationReadoutInterpretation
Autophagy 
 Electron microscopy Ultrastructure ↑ Autophagosomes Induction or block in maturation 
 Western blot analysis LC3 ↑ LC3-II band/LC3-I band Induction or block in maturation 
 Fluorescence microscopy GFP-LC3 ↑ GFP-LC3 puncta Induction or block in maturation 
Autophagy flux 
 Western blot analysis LC3 ± lysosome inhibitor ↑ LC3-II band/LC3-I band in the +inhibitor-treated sample Increased induction 
 Fluorescence microscopy GFP-LC3 ± lysosome inhibitor ↑ GFP-LC3 spots in the +inhibitor-treated sample Increased induction 
 Fluorescence microscopy mRFP-GFP-LC3 Yellow fluorescence: autophagosome ↑ Yellow/↑ red: increased induction 
  Red fluorescence: autolysosome ↑Yellow/↓ red: block in maturation 
AssayVisualizationReadoutInterpretation
Autophagy 
 Electron microscopy Ultrastructure ↑ Autophagosomes Induction or block in maturation 
 Western blot analysis LC3 ↑ LC3-II band/LC3-I band Induction or block in maturation 
 Fluorescence microscopy GFP-LC3 ↑ GFP-LC3 puncta Induction or block in maturation 
Autophagy flux 
 Western blot analysis LC3 ± lysosome inhibitor ↑ LC3-II band/LC3-I band in the +inhibitor-treated sample Increased induction 
 Fluorescence microscopy GFP-LC3 ± lysosome inhibitor ↑ GFP-LC3 spots in the +inhibitor-treated sample Increased induction 
 Fluorescence microscopy mRFP-GFP-LC3 Yellow fluorescence: autophagosome ↑ Yellow/↑ red: increased induction 
  Red fluorescence: autolysosome ↑Yellow/↓ red: block in maturation 

LC3 staining and the use of an autophagy reporter indicate that autophagy is induced as a late event in PDA progression, with elevated levels in the majority of invasive PDA tumors as compared with low-grade PanIN (75, 76). Against this backdrop, mouse genetic studies have highlighted the complex, context-specific functions of autophagy in tumorigenesis. Mice with deletion of ATG7 in the pancreas show progressive tissue damage (77, 78), consistent with the important quality control function of basal autophagy in this organ. This inflammatory state promotes the initial formation of PanIN precursor lesions in mice with engineered KRASG12D mutations, although these lesions show significant impairment in full malignant progression to PDA (75, 77, 78). Delayed PDA formation and extended survival are also observed in the KrasG12D;Trp53+/− model upon deletion of the lysosomal gene Plac8, which partially compromises autophagy (76). In contrast, the simultaneous activation of KRAS and homozygous deletion of TP53 (incurred during embryogenesis) negates the need for autophagy in PDA pathogenesis (77), although this genetic context is not thought to be representative of the genesis of most human PDAs. Taken as a whole, these data strongly suggest that autophagy is required for the development of invasive PDA.

The contextual effects of autophagy inhibition bear directly on the potential of targeting this process therapeutically. First, it is important to note that, unlike complete deletion of ATG7 (or ATG5) during pancreatic development, chloroquine treatment does not cause pancreatic damage, nor does it cooperate with KRAS in driving PanIN formation. Second, in human cell lines and PDX models, chloroquine inhibits tumor growth irrespective of TP53 genotype (78). Therefore, these data provide support for the pharmacologic targeting of autophagy as a PDA therapy. Although the mechanisms by which autophagy inhibition impairs tumorigenesis are presently under investigation, a number of key observations have been made. Autophagy inhibition in vitro and in vivo is cytostatic rather than cytotoxic. In vitro, this effect is associated with increased ROS and DNA damage as well as a decrease in oxidative phosphorylation. In turn, ROS scavengers or supplementation with pyruvate partially rescue growth, indicating that autophagy is required to maintain redox control and supply metabolic intermediates in PDA (65, 75). As discussed below, further examination of the interface of autophagy with cell metabolism will be an important step in the most effective deployment of autophagy inhibition to treat this cancer, potentially providing information regarding metabolic escape pathways and pointing toward combinatorial treatment strategies that may promote cell death rather than cytostasis.

PDAs Depend on Uptake of Extracellular Protein and Lipid

In addition to intracellular scavenging via autophagy, cells can use an additional scavenging pathway involving endocytosis-mediated bulk uptake of extracellular material, known as macropinocytosis (Fig. 3A). Studies by Commisso and colleagues (79) recently showed that KRAS-mutant cancer cells, including PDAs, upregulate macropinocytosis to import significant quantities of extracellular protein, which is ultimately delivered to lysosomes for proteolysis. Macropinocytosis of serum albumin was demonstrated to be a key source of AAs to fuel multiple metabolic pathways in PDA cells and to support growth upon glutamine restriction. Moreover, treatment of PDA cells with inhibitors of endocytosis that block albumin uptake impaired proliferation in vitro and tumor growth in vivo. Importantly, high levels of macropinocytic uptake are observed in PDA GEM models and in human PDA tumors (29). Thus, there is considerable interest in fully understanding the contributions of this pathway to PDA metabolism and in potentially targeting it therapeutically in KRAS-mutant cancers.

Other components of the extracellular milieu may also serve as critical sources of nutrients, including lipids. Although the overall abundance of lipid species in PDA is limited, with reduced amounts of fatty acids, lipids, and choline-containing compounds compared with normal pancreatic tissues (31, 80), the tumor cells appear to have efficient means for their retrieval. For example, KRASG12D transformation of immortalized pancreatic ductal epithelial cells (HPNE) induces increased scavenging of extracellular lipids (lysophospholipids) as an alternative source of fatty acids (81). Although a role for macropinocytosis is not clear, active uptake of fatty acids contrasts to the common view that cancer cells synthesize the majority of their nonessential fatty acids de novo and suggests a shift in the origin of fatty acid pools in the cell occurs downstream of oncogenic KRAS. In addition, PDA cells were reported to exhibit increased acquisition of cholesterol, in part through enhanced expression of the low-density lipoprotein receptor (LDLR; ref. 82). Inhibition of LDLR led to alterations in cholesterol distribution in the cell and a decrease in PDA growth both in vitro and in vivo. The detailed assessment of lipid metabolism in PDA growth is an important topic for future investigation. Nevertheless, taken together, these observations show that PDA cells orchestrate multiple nutrient scavenging pathways as sources of additional nutrients. Further discussion of dietary lipids and obesity in PDA pathogenesis is presented in the section on systemic metabolism, below.

Lysosome Activation: A Novel Hallmark of PDA

The major scavenging pathways in PDA, autophagy and macropinocytosis, converge at the lysosome, where cargo is digested by over 40 resident lysosomal acid hydrolases (lipases, proteases, glycosidases, acid phosphatases, and sulfatases), which are functional in the acidic environment of the lysosome (Fig. 3B). Changes in lysosome composition and function have been observed in cancer cells (83). Indeed, a recent study demonstrated that PDA specimens from treatment-naïve patients had striking increases in the number of lysosomes compared with matched normal pancreatic tissue (84). This finding indicates that elevations in lysosome biogenesis and function may be integral to the nutrient-scavenging program, ensuring efficient breakdown and recycling of cellular components and endocytosed material. Moreover, it suggests that there may be coordination between scavenging pathways and lysosome function in cancer.

The MiT/TFE family of basic helix–loop–helix transcription factors (MITF, TFE3, and TFEB) have been identified as central regulators of the biogenesis and function of the autophagy–lysosome system in PDA (84). TFEB was first shown by the Ballabio laboratory to be a master transcriptional regulator of an autophagy–lysosome transcriptional program through direct binding to a consensus sequence present in the regulatory regions of essential autophagy and lysosome genes (85–87). In follow-up studies, the MiT/TFE factors were shown to be components of an mTORC1-regulated acute stress response mechanism in normal cells (88–90). Under nutrient-rich conditions, mTOR is activated and localized to the lysosome, where it phosphorylates and inactivates the MiT/TFE proteins. Conversely, upon starvation, mTOR is switched off, enabling nuclear translocation of unphosphorylated MiT/TFE proteins. Together, these studies highlight a lysosome-to-nucleus signaling pathway that monitors the cell's nutritional status and adjusts catabolic activity accordingly.

In PDA cell lines and patient-derived PDA cultures, the MiT/TFE proteins bypass mTORC1-mediated surveillance and are constitutively localized in the nucleus regardless of external nutrient availability (84). This constitutive nuclear localization is mediated through binding to nuclear import proteins (including importin 8), which are overexpressed in PDA. Inactivation of MiT/TFE proteins in PDA cells results in downregulation of autophagy and lysosome genes, defective lysosomal function, and complete compromise in both autophagic flux and degradation of macropinocytosis-derived protein. Consequently, cell proliferation and tumor growth are significantly impaired. Collectively, these data show that by governing both autophagic flux and lysosomal catabolism, the MiT/TFE proteins support an integrated cellular clearance program that enables efficient processing of cargo from autophagy as well as macropinocytosis. Thus, PDAs appear to maximize growth processes associated with high mTOR activity while simultaneously benefiting from the metabolic fine-tuning and adaptation to stress afforded by activation of catabolic pathways. Interestingly, the MiT/TFE proteins are established oncogenes that are activated by genomic amplification or translocation in melanomas, renal cell carcinomas, and in alveolar soft part sarcoma (91), although contributions of autophagy regulation in these settings have not been explored to date.

What Are the Products of Lysosome Degradation?

As noted above, autophagy activation and macropinocytosis represent hardwired programs essential for metabolic adaptation and growth of PDA cell lines and tumors. A precise understanding of which specific metabolite pools are recovered through autolysosome-mediated degradation and how PDA cells use these pools will be critical to deciphering the metabolic reprogramming that sustains these tumors. Accordingly, metabolomics studies in cells following knockdown of the MiT/TFE proteins or of ATG5, or treatment with lysosome inhibitors, revealed a marked drop in intracellular AA levels, even in full nutrient conditions (84). These differences did not reflect broad changes in the rate of AA import or export and were not seen in nontransformed pancreatic cells. These findings indicate that autolysosome activation has PDA-specific functions in maintaining intracellular AA stores. Similar decreases in intracellular AA levels have also been observed following proteosome inhibition in yeast, Drosophila, and various mammalian cell lines despite exposure to full external nutrient conditions (92). Thus, catabolic processes supply a significant fraction of internal AA that is independent of import from the external environment in PDA. These observations raise the intriguing possibility that distinct metabolite pools may fuel different biologic processes. If so, how might this segregation occur and what factors dictate this partitioning? Detailed metabolite tracing experiments will provide insight into how these AA pools might be incorporated into different cellular reactions.

Beyond compensating for a paucity of nutrients supplied from the vasculature, the enhanced scavenging capacity of PDA cells may also serve an important quality control mechanism. Although initially thought to function as a nonselective method for degradation of cytoplasmic content, recent studies have shown that autophagosomes can sequester and degrade specific cargo (93, 94). This selective breakdown of protein may also be essential for functional maintenance or remodeling of the PDA cellular proteome, a process known as proteostasis. Cancer cells are often characterized by increased rates of protein synthesis, due to activation of oncogenic signaling pathways or extrinsic factors such as hypoxia or nutrient deprivation, which places a heavy burden on the endoplasmic reticulum (ER) for enhanced protein folding capacity. Adaptive responses to ER stress, such as autophagy, ensure efficient clearance of misfolded protein species that can impair cell function (95). Similarly, removal of damaged organelles, particularly mitochondria, is an important function of autophagy in cancer and has been shown to influence the malignant progression of lung tumors (65–67, 71).

Autophagy has also been linked to resistance to radiotherapy and cytotoxic chemotherapy in several cancer types, including PDA (96–98). Both the quality-control mechanisms of autophagy and the upregulation of internally generated nutrient sources may cooperate to enhance overall cellular fitness and increase metabolic resilience, thereby sustaining tumor cell survival under these conditions (99, 100). Thus, in addition to treatment of autophagy-addicted tumors, combination strategies incorporating autophagy inhibition may prevent or delay therapy resistance or increase the effectiveness of anticancer drugs in multiple tumor settings.

Systemic conditions, such as obesity and diabetes, have been linked to the onset and progression of PDA, suggesting that alterations in whole-body metabolism contribute to the pathogenesis of this cancer. Recent experimental studies support and extend this notion, revealing complex reciprocal interactions between somatic physiologic processes and the tumor cells that at least partially involve modulation of metabolism.

Obesity and Diabetes in PDA Pathogenesis

Obesity is an established risk factor for PDA in both men and women, increasing risk by an estimated 20% to 50%, as observed across multiple large pooled studies and meta-analyses (101). Moreover, the magnitude of risk increases in proportion to body mass index (BMI) in obese individuals. Consistent with an impact on disease initiation, obesity is also associated with increased incidence of PanIN lesions in otherwise normal pancreatic tissue (102). In addition, obesity appears to influence disease progression as well as the behavior of advanced tumors because patients with an elevated BMI prediagnosis are more likely to present with advanced-stage metastatic PDA at diagnosis compared with healthy-weight patients, and these patients show decreased overall survival times (103, 104).

In agreement with these epidemiologic data, administration of a high-fat/high-calorie diet (HFHCD) in multiple KRAS-mutant mouse models accelerates the development of early PanIN lesions and increases their progression to PDA (105, 106). Conversely, calorie-restricted diets have been shown to delay PanIN progression in KRAS-mutant mice (107). HFHCD was associated with activation of fibrosis and inflammatory pathways (e.g., COX2 and TNFα) and increased immune infiltrate in the premalignant pancreatic lesions, although these studies do not establish whether this effect is a cause rather than a consequence of accelerated tumorigenesis. Although these models showed some differences regarding the impact of HFHCD on insulin sensitivity and weight gain, they broadly support a connection between increased dietary intake and PDA risk. On the basis of the biologic alterations observed in mouse models and the aggressive features of obesity-associated PDA in humans, it will be of interest to determine whether PDA arising in this setting has distinct genomic features and differences in metabolic circuitry.

In addition to serving as substrates for anabolic metabolism and energy generation, lipids can act as important signaling molecules (e.g., prostaglandins and leukotrienes; ref. 108). Accordingly, additional studies have explored the role of specific lipid species in PDA pathogenesis using mouse models. Bioactive lipids containing omega-3 polyunsaturated fatty acids (n-3 PUFA), which have anti-inflammatory properties, were shown to strongly suppress PanIN progression and PDA development in the Ptf1Cre/+−;LSL-KrasG12D mouse model (109, 110). This series of findings on dietary intake and dietary supplementation appears to have implications for PDA prevention, and may be particularly relevant for the management of individuals at high risk for PDA, such as those with hereditary PDA syndromes.

The potential role of diabetes in PDA pathogenesis has long been under debate; however, recent work has provided considerable clarity in this regard, suggesting a “bidirectional” relationship between the two conditions (Fig. 4). First, long-standing type II diabetes (<2–8 years) correlates with an approximately 1.5- to 2-fold increased risk of PDA development (111, 112). The specific clinical features of diabetes that contribute to PDA risk have not been fully established. Interestingly, a large prospective case–control study of individuals without diabetes history showed an association between PDA and circulating markers of insulin resistance (e.g., increased pro-insulin levels), but not with islet cell dysfunction or hyperglycemia (Fig. 4A; ref. 113). This is in line with the reported increased PDA risk in diabetics treated with insulin or insulin secretagogues and decreased risk in those treated with the insulin sensitizer metformin (114), although a systematic meta-analysis concluded that additional prospective studies are still needed to support these associations (114). It is not known whether PDA arising in the setting of existing diabetes has distinct genomic profiles. Nevertheless, it is notable that patients with type II diabetes exhibit decreased overall survival compared with nondiabetic PDA patients (115), potentially suggesting differences in tumor biology.

Figure 4.

PDA is linked to alterations in whole-body metabolism. A, conditions associated with altered systemic metabolism—namely long-standing diabetes and obesity—are associated with increased PDA risk. In the case of diabetes, the increased secretion of islet-derived factors such as insulin may contribute to PDA development. B, PDAs can reciprocally induce diabetes as a paraneoplastic syndrome (referred to as PDA-induced diabetes or recent-onset diabetes) by secretion of tumor-associated factors (e.g., adrenomedullin) that cause β-cell dysfunction. C, advanced PDA is associated with cachexia, a condition involving weight loss and altered function of several metabolic tissues (skeletal muscle, liver, and adipose tissue). Cachexia is thought to be induced by inflammatory mediators and cytokines produced by the PDA cells themselves as well as components of the PDA microenvironment. In addition, increased pools of circulating branched chain AAs (BCAA) are an early sign of PDA onset, and may also be liberated from the muscle prior to clinically evident cachexia. These BCAA and the breakdown products of muscle and adipose tissue in cachexia may in turn serve as fuel sources that feed tumor growth.

Figure 4.

PDA is linked to alterations in whole-body metabolism. A, conditions associated with altered systemic metabolism—namely long-standing diabetes and obesity—are associated with increased PDA risk. In the case of diabetes, the increased secretion of islet-derived factors such as insulin may contribute to PDA development. B, PDAs can reciprocally induce diabetes as a paraneoplastic syndrome (referred to as PDA-induced diabetes or recent-onset diabetes) by secretion of tumor-associated factors (e.g., adrenomedullin) that cause β-cell dysfunction. C, advanced PDA is associated with cachexia, a condition involving weight loss and altered function of several metabolic tissues (skeletal muscle, liver, and adipose tissue). Cachexia is thought to be induced by inflammatory mediators and cytokines produced by the PDA cells themselves as well as components of the PDA microenvironment. In addition, increased pools of circulating branched chain AAs (BCAA) are an early sign of PDA onset, and may also be liberated from the muscle prior to clinically evident cachexia. These BCAA and the breakdown products of muscle and adipose tissue in cachexia may in turn serve as fuel sources that feed tumor growth.

Close modal

Importantly, in addition to being a risk factor, diabetes can also signal the onset of PDA (101). In particular, patients newly diagnosed with diabetes have an 8-fold increased risk of developing PDA within the next 36 months over the general population. It is estimated that approximately 34% of PDA patients have new-onset diabetes (also referred to as pancreatic cancer–induced diabetes) at the time of cancer diagnosis, and that this group represents up to 75% of PDA patients with diabetes. A large retrospective study monitoring blood glucose levels found evidence of diabetes caused by PDA starting 2 to 3 years prior to diagnosis of the cancer (116). Correspondingly, rather than reflecting destruction of islets and pancreatic parenchyma, this condition appears to be a paraneoplastic syndrome arising due to secretion of factors from the tumor cells, such as adrenomedullin, which inhibits insulin secretion by β-cells (Fig. 4B; refs. 117, 118). Consistent with this, new-onset diabetes resolves in some cases following tumor resection, whereas patients with long-standing diabetes have persistent disease following surgery (119). Because new-onset diabetes signals subclinical malignancy, it may offer approaches for early cancer diagnosis. However, given that type II diabetes is 100 times more common than pancreatic cancer–induced diabetes, the potential of using the latter condition for pancreatic cancer screening will require additional biomarkers distinguishing these conditions.

On the basis of the associations between PDA and whole-body metabolism, there is considerable interest in understanding the impact of the widely used antidiabetic drugs on PDA risk as well as the therapeutic effects of these drugs in established tumors. In particular, there are extensive studies conducted using the biguanide metformin in this setting. Metformin is a mitochondrial electron transport chain complex I inhibitor that functions, in part, via inhibiting ATP synthesis and thereby activating AMPK signaling as well as inhibiting the PKA pathway (120). In addition to decreasing gluconeogenesis in the liver and decreasing blood glucose levels, metformin inhibits anabolic metabolism and increases energy generation in peripheral tissues and cancer cells (121, 122). The basis of the widely observed antiproliferative effects of metformin observed in cancer cells in vitro and the antitumor effects seen in vivo have been attributed variously to AMPK activation, loss of TCA cycle intermediates, and more systemic effects (122, 123).

As noted above, retrospective studies have given inconsistent results regarding the association between use of metformin and PDA risk in diabetics. On the other hand, studies conducted in a mutant KRAS GEM model of PDA show that preventative treatment with metformin led to a decrease in the progression of PanIN to invasive PDA (124). In addition, metformin was found to significantly reduce the growth of human and murine PDA xenografts (125, 126), perhaps relating to reduction of glucose levels, anti-inflammatory effects, or direct effects on tumor cell metabolism via mitochondrial complex I inhibition. Evaluation of metformin as an anticancer therapeutic is currently ongoing in a number of clinical trials testing combinations of chemotherapy with this drug in metastatic PDA patients (Table 1).

Cachexia in PDA

Given the pronounced alterations in cell metabolism associated with PDA pathogenesis, there is considerable interest in the identification of metabolic biomarkers for early detection. Notably, by conducting a prospective study profiling metabolite changes in prediagnostic serum from four large cohorts of PDA patients versus matched controls, Mayers and colleagues (127) found that elevated levels of circulating branched chain AAs (BCAA) are an independent predictive marker of increased risk (2-fold) of developing future PDA. This increase was present early in disease progression (2–5 years prior to tumor diagnosis) and preceded clinically evident cachexia, the process of skeletal muscle wasting and loss of body fat. Nevertheless, it is likely that the BCAA source is from early stages of tissue breakdown, pointing to a tumor-associated secreted factor that influences whole-body metabolic homeostasis during PDA progression (Fig. 4C). Whether these BCAAs directly nourish the evolving tumor and promote its growth is currently unknown, although these observations suggest an additional mechanism by which PDAs may enhance their acquisition of nutrients. Such utilization of BCAAs for tumor growth is suggested by the increases in cell proliferation and tumor volume following administration of the BCAA leucine in a subcutaneous tumor model of PDA (128). Along these lines, it is also worth noting that cachexia itself is associated with more aggressive PDA tumors and poor prognosis, perhaps reflecting access of the tumor cells to substrates derived from lipolysis, protein breakdown, and systemic changes in glucose metabolism (127).

The signals inducing cachexia remain under investigation and both components of the tumor stroma as well as the neoplastic cells are thought to contribute to the process. Infiltration of lymphocytes and tumor-associated fibroblasts is detected during early stages of the disease, and the cytokines and inflammatory mediators secreted by these cells, including TNFα and IL6, have been implicated in promoting cachexia (129). There is also evidence that adrenomedullin produced by PDA cells may have lipolytic activity on adipose tissue (130).

Vitamin D

Metabolite levels can also have protective functions in relation to PDA development. Notably, high circulating levels of vitamin D have been associated with reduced risk of PDA in a large prospective study (131). The basis for this effect is not clear. However, it is notable that the activation state of PSCs has recently been shown to be under the control of vitamin D receptor (VDR) signaling (26). Activated PSCs promote inflammation and may support PDA growth, whereas a VDR agonist was shown to revert activation of PSCs to a quiescent state. Thus, vitamin D may act, in part, to reduce tumor-promoting fibrosis and inflammation. The vitamin D analogue paricalcitol is presently being tested in clinical trials in PDA on the basis of its antifibrotic effects and potential to improve delivery of cytotoxic agents administered concurrently (Table 1).

Taken as a whole, it is increasingly apparent that alterations in whole-body metabolism can significantly influence disease pathogenesis and patient outcomes in PDA. With this information comes the promise that the development of suitable assays to detect predictive biomarkers for cancer development, to devise chemopreventative strategies for high-risk individuals, and to assess metabolic features of advanced cancers may allow earlier intervention as well as guide treatment strategies.

The superior adaptive capacity and ability to rewire their metabolism allows for sustained growth of PDA cells, but also imparts vulnerabilities that may be targeted therapeutically. On the basis of this concept, clinical trials aimed at disturbing cancer metabolism are ongoing (Table 1). Treatment with HCQ aims to impair lysosome function and thus block output from autophagy and macropinocytosis, and is currently being tested in combination with a number of chemotherapy regimens. Although this drug is well tolerated in patients, the need for micromolar levels for activity and lack of accurate measures of pharmacology have complicated interpretations of the disappointing early clinical results (132). The future development of alternative, more potent, autophagy/lysosome inhibitors (e.g., targeting upstream kinases of the autophagy cascade; ULK1 and VPS34; ref. 133), coupled with intermittent dosing regimens, has the potential to have real efficacy in PDA. Moreover, a better understanding of the roles of autophagy in PDA metabolism and a more complete elucidation of metabolic adaptations to autophagy inhibition (such as the roles of increased glycolysis; ref. 61) may help to define combination approaches to change the effects of this treatment from cytostasis to cytotoxicity. Inhibition of parallel catabolic pathways such as proteasome-mediated degradation is one such approach that may have synergistic effects with autophagy inhibition.

As noted above, KRAS is a critical driver of proliferation and a master regulator of metabolic rewiring in PDA. In the context of targeting the metabolic pathways associated with KRAS activation, it is as yet unclear how best to target these enzymes as a cancer therapy, as many have essential functions in noncancer cells. For example, targeting GLUT1 or other glycolytic enzymes may be associated with severe toxicities due to their near-ubiquitous requirement in most normal tissues. In contrast, targeting of LDHA may be a well-tolerated therapy strategy, because human syndromes associated with decreased LDHA activity do not present severe abnormalities in organ function in adults (35). In addition, renewed efforts to generate inhibitors of KRAS are currently under way as part of the National RAS Initiative (134). Anticipating the development of such agents and the potential that resistance mechanisms to KRAS inhibition may eventually arise, Viale and colleagues developed a GEM model of resistance to genetic inactivation of KRAS in PDA. They found that a series of adaptive metabolic alterations, including elevation in oxidative phosphorylation and potentiation of autophagy, were required to mediate survival following KRAS extinction, thus suggesting combinatorial strategies for future KRAS-targeted therapy (135). Given the recent emergence of cancer immunotherapy, an added consideration for the deployment of drugs that block tumor cell metabolism is their potential effects on tumor immunity, and on the efficacy of T-cell checkpoint inhibition and other approaches of immune activation. As activated immune and stromal cells exhibit a number of metabolic changes that are common with tumor cells (136–140), it will be important to determine whether targeting these metabolic pathways interferes with (or enhances) immune function, thereby informing potential combination therapies.

Metabolic rewiring is central to the pathogenesis of PDA and is a critical component of the tumorigenic program driven by KRAS, the signature mutation in this malignancy. A key current challenge is to more fully define how nutrient substrates are generated and used in these tumors and to understand how the multiple different cooperating genomic alterations found in PDA influence these processes. Many important areas, such as lipid metabolism, mitochondrial function, and the role of nutrient sensing transcription factors, remain to be explored. With the development of more precise techniques for dynamic measurement of metabolic reactions both in vitro and in vivo, coupled with use of faithful cancer models, significant progress in our understanding of the functions of these pathways in disease progression is on the horizon. In the future, information regarding the metabolic dependencies of PDA and the interplay between the tumor, systemic metabolism, and immune function holds promise for highlighting a path toward the development of novel cancer diagnostics and therapeutics.

No potential conflicts of interest were disclosed.

The authors sincerely apologize to their colleagues for being unable to cite all of the important work in this area due to space constraints. The authors thank Brian Wolpin for critical reading of the manuscript.

This work was supported by grants from the NIH (P50CA1270003, P01 CA117969-07, and R01 CA133557-05) and the Linda J. Verville Cancer Research Foundation to N. Bardeesy and a Hirshberg Foundation for Pancreatic Cancer seed grant to R.M. Perera.

1.
Ryan
DP
,
Hong
TS
,
Bardeesy
N
. 
Pancreatic adenocarcinoma
.
N Engl J Med
2014
;
371
:
2140
1
.
2.
Maitra
A
,
Hruban
RH
. 
Pancreatic cancer
.
Annu Rev Pathol
2008
;
3
:
157
88
.
3.
Morris
JPt
,
Wang
SC
,
Hebrok
M
. 
KRAS, hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
.
Nat Rev Cancer
2010
;
10
:
683
95
.
4.
Aguirre
AJ
,
Bardeesy
N
,
Sinha
M
,
Lopez
L
,
Tuveson
DA
,
Horner
J
, et al
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
.
Genes Dev
2003
;
17
:
3112
26
.
5.
Collisson
EA
,
Sadanandam
A
,
Olson
P
,
Gibb
WJ
,
Truitt
M
,
Gu
S
, et al
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
.
Nat Med
2011
;
17
:
500
3
.
6.
Hingorani
SR
,
Petricoin
EF
,
Maitra
A
,
Rajapakse
V
,
King
C
,
Jacobetz
MA
, et al
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
.
Cancer Cell
2003
;
4
:
437
50
.
7.
Singh
A
,
Greninger
P
,
Rhodes
D
,
Koopman
L
,
Violette
S
,
Bardeesy
N
, et al
A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival
.
Cancer Cell
2009
;
15
:
489
500
.
8.
Ying
H
,
Kimmelman
AC
,
Lyssiotis
CA
,
Hua
S
,
Chu
GC
,
Fletcher-Sananikone
E
, et al
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
.
Cell
2012
;
149
:
656
70
.
9.
Collins
MA
,
Bednar
F
,
Zhang
Y
,
Brisset
JC
,
Galban
S
,
Galban
CJ
, et al
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
.
J Clin Invest
2012
;
122
:
639
53
.
10.
Yachida
S
,
Iacobuzio-Donahue
CA
. 
Evolution and dynamics of pancreatic cancer progression
.
Oncogene
2013
;
32
:
5253
60
.
11.
Yachida
S
,
Jones
S
,
Bozic
I
,
Antal
T
,
Leary
R
,
Fu
B
, et al
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
.
Nature
2010
;
467
:
1114
7
.
12.
Yachida
S
,
White
CM
,
Naito
Y
,
Zhong
Y
,
Brosnan
JA
,
Macgregor-Das
AM
, et al
Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors
.
Clin Cancer Res
2012
;
18
:
6339
47
.
13.
Bardeesy
N
,
Aguirre
AJ
,
Chu
GC
,
Cheng
KH
,
Lopez
LV
,
Hezel
AF
, et al
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse
.
Proc Natl Acad Sci U S A
2006
;
103
:
5947
52
.
14.
Bardeesy
N
,
Cheng
KH
,
Berger
JH
,
Chu
GC
,
Pahler
J
,
Olson
P
, et al
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
.
Genes Dev
2006
;
20
:
3130
46
.
15.
Hingorani
SR
,
Wang
L
,
Multani
AS
,
Combs
C
,
Deramaudt
TB
,
Hruban
RH
, et al
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
.
Cancer Cell
2005
;
7
:
469
83
.
16.
Whittle
MC
,
Izeradjene
K
,
Rani
PG
,
Feng
L
,
Carlson
MA
,
DelGiorno
KE
, et al
RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma
.
Cell
2015
;
161
:
1345
60
.
17.
Biankin
AV
,
Waddell
N
,
Kassahn
KS
,
Gingras
MC
,
Muthuswamy
LB
,
Johns
AL
, et al
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
.
Nature
2012
;
491
:
399
405
.
18.
Waddell
N
,
Pajic
M
,
Patch
AM
,
Chang
DK
,
Kassahn
KS
,
Bailey
P
, et al
Whole genomes redefine the mutational landscape of pancreatic cancer
.
Nature
2015
;
518
:
495
501
.
19.
Kimmelman
AC
. 
Metabolic dependencies in RAS-driven cancers
.
Clin Cancer Res
2015
;
21
:
1828
34
.
20.
White
E
. 
Exploiting the bad eating habits of Ras-driven cancers
.
Genes Dev
2013
;
27
:
2065
71
.
21.
Neesse
A
,
Michl
P
,
Frese
KK
,
Feig
C
,
Cook
N
,
Jacobetz
MA
, et al
Stromal biology and therapy in pancreatic cancer
.
Gut
2010
;
60
:
861
8
.
22.
Hingorani
SR
. 
Cellular and molecular conspirators in pancreas cancer
.
Carcinogenesis
2014
;
35
:
1435
.
23.
Lee
JJ
,
Perera
RM
,
Wang
H
,
Wu
DC
,
Liu
XS
,
Han
S
, et al
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
.
Proc Natl Acad Sci U S A
2014
;
111
:
E3091
100
.
24.
Ozdemir
BC
,
Pentcheva-Hoang
T
,
Carstens
JL
,
Zheng
X
,
Wu
CC
,
Simpson
TR
, et al
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival
.
Cancer Cell
2014
;
25
:
719
34
.
25.
Rhim
AD
,
Oberstein
PE
,
Thomas
DH
,
Mirek
ET
,
Palermo
CF
,
Sastra
SA
, et al
Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma
.
Cancer Cell
2014
;
25
:
735
47
.
26.
Sherman
MH
,
Yu
RT
,
Engle
DD
,
Ding
N
,
Atkins
AR
,
Tiriac
H
, et al
Vitamin D receptor–mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy
.
Cell
2014
;
159
:
80
93
.
27.
Vonderheide
RH
,
Bayne
LJ
. 
Inflammatory networks and immune surveillance of pancreatic carcinoma
.
Curr Opin Immunol
2013
;
25
:
200
5
.
28.
Kraman
M
,
Bambrough
PJ
,
Arnold
JN
,
Roberts
EW
,
Magiera
L
,
Jones
JO
, et al
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha
.
Science
2010
;
330
:
827
30
.
29.
Kamphorst
JJ
,
Nofal
M
,
Commisso
C
,
Hackett
SR
,
Lu
W
,
Grabocka
E
, et al
Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein
.
Cancer Res
2015
;
75
:
544
53
.
30.
Stylianopoulos
T
,
Martin
JD
,
Chauhan
VP
,
Jain
SR
,
Diop-Frimpong
B
,
Bardeesy
N
, et al
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors
.
Proc Natl Acad Sci U S A
2012
;
109
:
15101
8
.
31.
Ma
X
,
Zhao
X
,
Ouyang
H
,
Sun
F
,
Zhang
H
,
Zhou
C
, et al
The metabolic features of normal pancreas and pancreatic adenocarcinoma: preliminary result of in vivo proton magnetic resonance spectroscopy at 3.0 T
.
J Comput Assist Tomogr
2011
;
35
:
539
43
.
32.
Efeyan
A
,
Comb
WC
,
Sabatini
DM
. 
Nutrient-sensing mechanisms and pathways
.
Nature
2015
;
517
:
302
10
.
33.
Hardie
DG
. 
AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function
.
Genes Dev
2011
;
25
:
1895
908
.
34.
Zoncu
R
,
Efeyan
A
,
Sabatini
DM
. 
mTOR: from growth signal integration to cancer, diabetes and ageing
.
Nat Rev Mol Cell Biol
2011
;
12
:
21
35
.
35.
DeBerardinis
RJ
,
Thompson
CB
. 
Cellular metabolism and disease: what do metabolic outliers teach us?
Cell
2012
;
148
:
1132
44
.
36.
Guo
JY
,
Xia
B
,
White
E
. 
Autophagy-mediated tumor promotion
.
Cell
2013
;
155
:
1216
9
.
37.
Sousa
CM
,
Kimmelman
AC
. 
The complex landscape of pancreatic cancer metabolism
.
Carcinogenesis
2014
;
35
:
1441
50
.
38.
DeBerardinis
RJ
,
Lum
JJ
,
Hatzivassiliou
G
,
Thompson
CB
. 
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation
.
Cell Metab
2008
;
7
:
11
20
.
39.
Koppenol
WH
,
Bounds
PL
,
Dang
CV
. 
Otto Warburg's contributions to current concepts of cancer metabolism
.
Nat Rev Cancer
2011
;
11
:
325
37
.
40.
Weinberg
F
,
Hamanaka
R
,
Wheaton
WW
,
Weinberg
S
,
Joseph
J
,
Lopez
M
, et al
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
.
Proc Natl Acad Sci U S A
2010
;
107
:
8788
93
.
41.
Kitasato
Y
,
Yasunaga
M
,
Okuda
K
,
Kinoshita
H
,
Tanaka
H
,
Okabe
Y
, et al
Maximum standardized uptake value on 18F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography and glucose transporter-1 expression correlates with survival in invasive ductal carcinoma of the pancreas
.
Pancreas
2014
;
43
:
1060
5
.
42.
Yamamoto
T
,
Sugiura
T
,
Mizuno
T
,
Okamura
Y
,
Aramaki
T
,
Endo
M
, et al
Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma
.
Ann Surg Oncol
2014
;
22
:
677
84
.
43.
Le
A
,
Cooper
CR
,
Gouw
AM
,
Dinavahi
R
,
Maitra
A
,
Deck
LM
, et al
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
.
Proc Natl Acad Sci U S A
2010
;
107
:
2037
42
.
44.
Guillaumond
F
,
Leca
J
,
Olivares
O
,
Lavaut
MN
,
Vidal
N
,
Berthezene
P
, et al
Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma
.
Proc Natl Acad Sci U S A
2013
;
110
:
3919
24
.
45.
Parks
SK
,
Chiche
J
,
Pouyssegur
J
. 
Disrupting proton dynamics and energy metabolism for cancer therapy
.
Nat Rev Cancer
2013
;
13
:
611
23
.
46.
Baek
G
,
Tse
YF
,
Hu
Z
,
Cox
D
,
Buboltz
N
,
McCue
P
, et al
MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies
.
Cell Rep
2014
;
9
:
2233
49
.
47.
Roland
CL
,
Arumugam
T
,
Deng
D
,
Liu
SH
,
Philip
B
,
Gomez
S
, et al
Cell surface lactate receptor GPR81 is crucial for cancer cell survival
.
Cancer Res
2014
;
74
:
5301
10
.
48.
Cui
J
,
Shi
M
,
Xie
D
,
Wei
D
,
Jia
Z
,
Zheng
S
, et al
FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression
.
Clin Cancer Res
2014
;
20
:
2595
606
.
49.
Shi
M
,
Cui
J
,
Du
J
,
Wei
D
,
Jia
Z
,
Zhang
J
, et al
A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer
.
Clin Cancer Res
2014
;
20
:
4370
80
.
50.
Guan
KL
,
Xiong
Y
. 
Regulation of intermediary metabolism by protein acetylation
.
Trends Biochem Sci
2010
;
36
:
108
16
.
51.
Hitosugi
T
,
Chen
J
. 
Post-translational modifications and the Warburg effect
.
Oncogene
2013
;
33
:
4279
85
.
52.
Zhao
D
,
Zou
SW
,
Liu
Y
,
Zhou
X
,
Mo
Y
,
Wang
P
, et al
Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer
.
Cancer Cell
2013
;
23
:
464
76
.
53.
Hensley
CT
,
Wasti
AT
,
DeBerardinis
RJ
. 
Glutamine and cancer: cell biology, physiology, and clinical opportunities
.
J Clin Invest
2013
;
123
:
3678
84
.
54.
Wise
DR
,
DeBerardinis
RJ
,
Mancuso
A
,
Sayed
N
,
Zhang
XY
,
Pfeiffer
HK
, et al
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
.
Proc Natl Acad Sci U S A
2008
;
105
:
18782
7
.
55.
Meister
A
,
Anderson
ME
. 
Glutathione
.
Annu Rev Biochem
1983
;
52
:
711
60
.
56.
Son
J
,
Lyssiotis
CA
,
Ying
H
,
Wang
X
,
Hua
S
,
Ligorio
M
, et al
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
.
Nature
2013
;
496
:
101
5
.
57.
Yang
H
,
Zhou
L
,
Shi
Q
,
Zhao
Y
,
Lin
H
,
Zhang
M
, et al
SIRT3-dependent GOT2 acetylation status affects the malate-aspartate NADH shuttle activity and pancreatic tumor growth
.
EMBO J
2015
;
34
:
1110
25
.
58.
DeNicola
GM
,
Karreth
FA
,
Humpton
TJ
,
Gopinathan
A
,
Wei
C
,
Frese
K
, et al
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
.
Nature
2011
;
475
:
106
9
.
59.
Mashimo
T
,
Pichumani
K
,
Vemireddy
V
,
Hatanpaa
KJ
,
Singh
DK
,
Sirasanagandla
S
, et al
Acetate is a bioenergetic substrate for human glioblastoma and brain metastases
.
Cell
2014
;
159
:
1603
14
.
60.
Marin-Valencia
I
,
Yang
C
,
Mashimo
T
,
Cho
S
,
Baek
H
,
Yang
XL
, et al
Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo
.
Cell Metab
2012
;
15
:
827
37
.
61.
Rabinowitz
JD
,
White
E
. 
Autophagy and metabolism
.
Science
2010
;
330
:
1344
8
.
62.
Kroemer
G
,
Marino
G
,
Levine
B
. 
Autophagy and the integrated stress response
.
Mol Cell
2010
;
40
:
280
93
.
63.
Levine
B
,
Kroemer
G
. 
Autophagy in the pathogenesis of disease
.
Cell
2008
;
132
:
27
42
.
64.
Cheong
H
,
Lindsten
T
,
Wu
J
,
Lu
C
,
Thompson
CB
. 
Ammonia-induced autophagy is independent of ULK1/ULK2 kinases
.
Proc Natl Acad Sci U S A
2011
;
108
:
11121
6
.
65.
Guo
JY
,
Chen
HY
,
Mathew
R
,
Fan
J
,
Strohecker
AM
,
Karsli-Uzunbas
G
, et al
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
.
Genes Dev
2011
;
25
:
460
70
.
66.
Guo
JY
,
Karsli-Uzunbas
G
,
Mathew
R
,
Aisner
SC
,
Kamphorst
JJ
,
Strohecker
AM
, et al
Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis
.
Genes Dev
2013
;
27
:
1447
61
.
67.
Karsli-Uzunbas
G
,
Guo
JY
,
Price
S
,
Teng
X
,
Laddha
SV
,
Khor
S
, et al
Autophagy is required for glucose homeostasis and lung tumor maintenance
.
Cancer Discov
2014
;
4
:
914
27
.
68.
Lock
R
,
Kenific
CM
,
Leidal
AM
,
Salas
E
,
Debnath
J
. 
Autophagy-dependent production of secreted factors facilitates oncogenic RAS-driven invasion
.
Cancer Discov
2014
;
4
:
466
79
.
69.
Lock
R
,
Roy
S
,
Kenific
CM
,
Su
JS
,
Salas
E
,
Ronen
SM
, et al
Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation
.
Mol Biol Cell
2011
;
22
:
165
78
.
70.
Morgan
MJ
,
Gamez
G
,
Menke
C
,
Hernandez
A
,
Thorburn
J
,
Gidan
F
, et al
Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent
.
Autophagy
2014
;
10
:
1814
26
.
71.
Rao
S
,
Tortola
L
,
Perlot
T
,
Wirnsberger
G
,
Novatchkova
M
,
Nitsch
R
, et al
A dual role for autophagy in a murine model of lung cancer
.
Nat Commun
2014
;
5
:
3056
.
72.
Strohecker
AM
,
Guo
JY
,
Karsli-Uzunbas
G
,
Price
SM
,
Chen
GJ
,
Mathew
R
, et al
Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors
.
Cancer Discov
2013
;
3
:
1272
85
.
73.
Wei
H
,
Wei
S
,
Gan
B
,
Peng
X
,
Zou
W
,
Guan
JL
. 
Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis
.
Genes Dev
2011
;
25
:
1510
27
.
74.
Xie
X
,
Koh
JY
,
Price
S
,
White
E
,
Mehnert
JM
. 
Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma
.
Cancer Discov
2015
;
5
:
410
23
.
75.
Yang
S
,
Wang
X
,
Contino
G
,
Liesa
M
,
Sahin
E
,
Ying
H
, et al
Pancreatic cancers require autophagy for tumor growth
.
Genes Dev
2011
;
25
:
717
29
.
76.
Kinsey
C
,
Balakrishnan
V
,
O'Dell
MR
,
Huang
JL
,
Newman
L
,
Whitney-Miller
CL
, et al
Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression
.
Cell Rep
2014
;
7
:
1143
55
.
77.
Rosenfeldt
MT
,
O'Prey
J
,
Morton
JP
,
Nixon
C
,
MacKay
G
,
Mrowinska
A
, et al
p53 status determines the role of autophagy in pancreatic tumour development
.
Nature
2013
;
504
:
296
300
.
78.
Yang
A
,
Rajeshkumar
NV
,
Wang
X
,
Yabuuchi
S
,
Alexander
BM
,
Chu
GC
, et al
Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations
.
Cancer Discov
2014
;
4
:
905
13
.
79.
Commisso
C
,
Davidson
SM
,
Soydaner-Azeloglu
RG
,
Parker
SJ
,
Kamphorst
JJ
,
Hackett
S
, et al
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
.
Nature
2013
;
497
:
633
7
.
80.
Yao
X
,
Zeng
M
,
Wang
H
,
Fei
S
,
Rao
S
,
Ji
Y
. 
Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results
.
Radiol Med
2012
;
117
:
780
8
.
81.
Kamphorst
JJ
,
Cross
JR
,
Fan
J
,
de Stanchina
E
,
Mathew
R
,
White
EP
, et al
Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids
.
Proc Natl Acad Sci U S A
2013
;
110
:
8882
7
.
82.
Guillaumond
F
,
Bidaut
G
,
Ouaissi
M
,
Servais
S
,
Gouirand
V
,
Olivares
O
, et al
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma
.
Proc Natl Acad Sci U S A
2015
;
112
:
2473
8
.
83.
Kallunki
T
,
Olsen
OD
,
Jaattela
M
. 
Cancer-associated lysosomal changes: friends or foes?
Oncogene
2012
;
32
:
1995
2004
.
84.
Perera
RM
,
Stoykova
S
,
Nicolay
BN
,
Ross
KN
,
Fitamant
J
,
Boukhali
M
, et al
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism
.
Nature
2015
;
524
:
361
5
.
85.
Sardiello
M
,
Palmieri
M
,
di Ronza
A
,
Medina
DL
,
Valenza
M
,
Gennarino
VA
, et al
A gene network regulating lysosomal biogenesis and function
.
Science
2009
;
325
:
473
7
.
86.
Settembre
C
,
Di Malta
C
,
Polito
VA
,
Garcia Arencibia
M
,
Vetrini
F
,
Erdin
S
, et al
TFEB links autophagy to lysosomal biogenesis
.
Science
2011
;
332
:
1429
33
.
87.
Settembre
C
,
Fraldi
A
,
Medina
DL
,
Ballabio
A
. 
Signals from the lysosome: a control centre for cellular clearance and energy metabolism
.
Nat Rev Mol Cell Biol
2013
;
14
:
283
96
.
88.
Martina
JA
,
Diab
HI
,
Lishu
L
,
Jeong
AL
,
Patange
S
,
Raben
N
, et al
The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris
.
Sci Signal
2014
;
7
:
ra9
.
89.
Roczniak-Ferguson
A
,
Petit
CS
,
Froehlich
F
,
Qian
S
,
Ky
J
,
Angarola
B
, et al
The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis
.
Sci Signal
2012
;
5
:
ra42
.
90.
Settembre
C
,
Zoncu
R
,
Medina
DL
,
Vetrini
F
,
Erdin
S
,
Huynh
T
, et al
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB
.
EMBO J
2012
;
31
:
1095
108
.
91.
Haq
R
,
Fisher
DE
. 
Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer
.
J Clin Oncol
2011
;
29
:
3474
82
.
92.
Suraweera
A
,
Munch
C
,
Hanssum
A
,
Bertolotti
A
. 
Failure of amino acid homeostasis causes cell death following proteasome inhibition
.
Mol Cell
2012
;
48
:
242
53
.
93.
Mancias
JD
,
Wang
X
,
Gygi
SP
,
Harper
JW
,
Kimmelman
AC
. 
Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy
.
Nature
2014
;
509
:
105
9
.
94.
Mathew
R
,
Khor
S
,
Hackett
SR
,
Rabinowitz
JD
,
Perlman
DH
,
White
E
. 
Functional role of autophagy-mediated proteome remodeling in cell survival signaling and innate immunity
.
Mol Cell
2014
;
55
:
916
30
.
95.
Tameire
F
,
Verginadis
II
,
Koumenis
C
. 
Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: mechanisms and targets for therapy
.
Semin Cancer Biol
2015
;
3
:
3
15
.
96.
Hashimoto
D
,
Blauer
M
,
Hirota
M
,
Ikonen
NH
,
Sand
J
,
Laukkarinen
J
. 
Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs
.
Eur J Cancer
2014
;
50
:
1382
90
.
97.
Sui
X
,
Chen
R
,
Wang
Z
,
Huang
Z
,
Kong
N
,
Zhang
M
, et al
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
.
Cell Death Dis
2013
;
4
:
e838
.
98.
Wang
P
,
Zhang
J
,
Zhang
L
,
Zhu
Z
,
Fan
J
,
Chen
L
, et al
MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells
.
Gastroenterology
2013
;
145
:
1133
43
,
e12
.
99.
Thorburn
A
. 
Autophagy and its effects: making sense of double-edged swords
.
PLoS Biol
2014
;
12
:
e1001967
.
100.
White
E
. 
Deconvoluting the context-dependent role for autophagy in cancer
.
Nat Rev Cancer
2012
;
12
:
401
10
.
101.
Bracci
PM
. 
Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms
.
Mol Carcinog
2012
;
51
:
53
63
.
102.
Rebours
V
,
Gaujoux
S
,
d'Assignies
G
,
Sauvanet
A
,
Ruszniewski
P
,
Levy
P
, et al
Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN)
.
Clin Cancer Res
2015
;
21
:
3522
8
.
103.
Li
D
,
Morris
JS
,
Liu
J
,
Hassan
MM
,
Day
RS
,
Bondy
ML
, et al
Body mass index and risk, age of onset, and survival in patients with pancreatic cancer
.
JAMA
2009
;
301
:
2553
62
.
104.
Yuan
C
,
Bao
Y
,
Wu
C
,
Kraft
P
,
Ogino
S
,
Ng
K
, et al
Prediagnostic body mass index and pancreatic cancer survival
.
J Clin Oncol
2013
;
31
:
4229
34
.
105.
Khasawneh
J
,
Schulz
MD
,
Walch
A
,
Rozman
J
,
Hrabe de Angelis
M
,
Klingenspor
M
, et al
Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion
.
Proc Natl Acad Sci U S A
2009
;
106
:
3354
9
.
106.
Philip
B
,
Roland
CL
,
Daniluk
J
,
Liu
Y
,
Chatterjee
D
,
Gomez
SB
, et al
A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice
.
Gastroenterology
2013
;
145
:
1449
58
.
107.
Lanza-Jacoby
S
,
Yan
G
,
Radice
G
,
LePhong
C
,
Baliff
J
,
Hess
R
. 
Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer
.
Exp Biol Med
2013
;
238
:
787
97
.
108.
Wang
D
,
Dubois
RN
. 
Eicosanoids and cancer
.
Nat Rev Cancer
2010
;
10
:
181
93
.
109.
Mohammed
A
,
Janakiram
NB
,
Brewer
M
,
Duff
A
,
Lightfoot
S
,
Brush
RS
, et al
Endogenous n-3 polyunsaturated fatty acids delay progression of pancreatic ductal adenocarcinoma in Fat-1-p48(Cre/+)-LSL-Kras(G12D/+) mice
.
Neoplasia
2012
;
14
:
1249
59
.
110.
Strouch
MJ
,
Ding
Y
,
Salabat
MR
,
Melstrom
LG
,
Adrian
K
,
Quinn
C
, et al
A high omega-3 fatty acid diet mitigates murine pancreatic precancer development
.
J Surg Res
2011
;
165
:
75
81
.
111.
Huxley
R
,
Ansary-Moghaddam
A
,
Berrington de Gonzalez
A
,
Barzi
F
,
Woodward
M
. 
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
.
Br J Cancer
2005
;
92
:
2076
83
.
112.
Muniraj
T
,
Chari
ST
. 
Diabetes and pancreatic cancer
.
Minerva Gastroenterol Dietol
2012
;
58
:
331
45
.
113.
Wolpin
BM
,
Bao
Y
,
Qian
ZR
,
Wu
C
,
Kraft
P
,
Ogino
S
, et al
Hyperglycemia, insulin resistance, impaired pancreatic beta-cell function, and risk of pancreatic cancer
.
J Natl Cancer Inst
2013
;
105
:
1027
35
.
114.
Li
D
,
Yeung
SC
,
Hassan
MM
,
Konopleva
M
,
Abbruzzese
JL
. 
Antidiabetic therapies affect risk of pancreatic cancer
.
Gastroenterology
2009
;
137
:
482
8
.
115.
Yuan
C
,
Rubinson
DA
,
Qian
ZR
,
Wu
C
,
Kraft
P
,
Bao
Y
, et al
Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus
.
J Clin Oncol
2014
;
33
:
29
35
.
116.
Chari
ST
,
Leibson
CL
,
Rabe
KG
,
Timmons
LJ
,
Ransom
J
,
de Andrade
M
, et al
Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer
.
Gastroenterology
2008
;
134
:
95
101
.
117.
Aggarwal
G
,
Ramachandran
V
,
Javeed
N
,
Arumugam
T
,
Dutta
S
,
Klee
GG
, et al
Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice
.
Gastroenterology
2012
;
143
:
1510
7
,
e1
.
118.
Sah
RP
,
Nagpal
SJ
,
Mukhopadhyay
D
,
Chari
ST
. 
New insights into pancreatic cancer-induced paraneoplastic diabetes
.
Nat Rev Gastroenterol Hepatol
2013
;
10
:
423
33
.
119.
Pannala
R
,
Leirness
JB
,
Bamlet
WR
,
Basu
A
,
Petersen
GM
,
Chari
ST
. 
Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus
.
Gastroenterology
2008
;
134
:
981
7
.
120.
Baur
JA
,
Birnbaum
MJ
. 
Control of gluconeogenesis by metformin: does redox trump energy charge?
Cell Metab
2014
;
20
:
197
9
.
121.
Hardie
DG
. 
Molecular pathways: is AMPK a friend or a foe in cancer?
Clin Cancer Res
2015
;
21
:
3836
40
.
122.
Hardie
DG
. 
AMPK: positive and negative regulation, and its role in whole-body energy homeostasis
.
Curr Opin Cell Biol
2015
;
33
:
1
7
.
123.
Janzer
A
,
German
NJ
,
Gonzalez-Herrera
KN
,
Asara
JM
,
Haigis
MC
,
Struhl
K
. 
Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells
.
Proc Natl Acad Sci U S A
2014
;
111
:
10574
9
.
124.
Mohammed
A
,
Janakiram
NB
,
Brewer
M
,
Ritchie
RL
,
Marya
A
,
Lightfoot
S
, et al
Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling
.
Transl Oncol
2014
;
6
:
649
59
.
125.
Cifarelli
V
,
Lashinger
LM
,
Devlin
KL
,
Dunlap
SM
,
Huang
J
,
Kaaks
R
, et al
Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct MicroRNA-regulated mechanisms
.
Diabetes
2015
;
64
:
1632
42
.
126.
Kisfalvi
K
,
Moro
A
,
Sinnett-Smith
J
,
Eibl
G
,
Rozengurt
E
. 
Metformin inhibits the growth of human pancreatic cancer xenografts
.
Pancreas
2013
;
42
:
781
5
.
127.
Mayers
JR
,
Wu
C
,
Clish
CB
,
Kraft
P
,
Torrence
ME
,
Fiske
BP
, et al
Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development
.
Nat Med
2014
;
20
:
1193
8
.
128.
Liu
KA
,
Lashinger
LM
,
Rasmussen
AJ
,
Hursting
SD
. 
Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice
.
Cancer Metab
2014
;
2
:
6
.
129.
Fearon
KC
,
Glass
DJ
,
Guttridge
DC
. 
Cancer cachexia: mediators, signaling, and metabolic pathways
.
Cell Metab
2012
;
16
:
153
66
.
130.
Sagar
G
,
Sah
RP
,
Javeed
N
,
Dutta
SK
,
Smyrk
TC
,
Lau
JS
, et al
Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue
.
Gut
2015
Apr 28 [Epub ahead of print].
131.
Wolpin
BM
,
Ng
K
,
Bao
Y
,
Kraft
P
,
Stampfer
MJ
,
Michaud
DS
, et al
Plasma 25-hydroxyvitamin D and risk of pancreatic cancer
.
Cancer Epidemiol Biomarkers Prev
2011
;
21
:
82
91
.
132.
Wolpin
BM
,
Rubinson
DA
,
Wang
X
,
Chan
JA
,
Cleary
JM
,
Enzinger
PC
, et al
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma
.
Oncologist
2014
;
19
:
637
8
.
133.
Ronan
B
,
Flamand
O
,
Vescovi
L
,
Dureuil
C
,
Durand
L
,
Fassy
F
, et al
A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy
.
Nat Chem Biol
2014
;
10
:
1013
9
.
134.
McCormick
F
. 
KRAS as a therapeutic target
.
Clin Cancer Res
2015
;
21
:
1797
801
.
135.
Viale
A
,
Pettazzoni
P
,
Lyssiotis
CA
,
Ying
H
,
Sanchez
N
,
Marchesini
M
, et al
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
.
Nature
2014
;
517
:
205
8
.
136.
Balliet
RM
,
Capparelli
C
,
Guido
C
,
Pestell
TG
,
Martinez-Outschoorn
UE
,
Lin
Z
, et al
Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection
.
Cell Cycle
2011
;
10
:
4065
73
.
137.
Ertel
A
,
Tsirigos
A
,
Whitaker-Menezes
D
,
Birbe
RC
,
Pavlides
S
,
Martinez-Outschoorn
UE
, et al
Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism
.
Cell Cycle
2012
;
11
:
253
63
.
138.
O'Neill
LA
,
Hardie
DG
. 
Metabolism of inflammation limited by AMPK and pseudo-starvation
.
Nature
2013
;
493
:
346
55
.
139.
Rattigan
YI
,
Patel
BB
,
Ackerstaff
E
,
Sukenick
G
,
Koutcher
JA
,
Glod
JW
, et al
Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment
.
Exp Cell Res
2011
;
318
:
326
35
.
140.
Sotgia
F
,
Martinez-Outschoorn
UE
,
Howell
A
,
Pestell
RG
,
Pavlides
S
,
Lisanti
MP
. 
Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms
.
Annu Rev Pathol
2012
;
7
:
423
67
.